Grant of Canadian Patent for OptiMAL

Fusion Antibodies secures Canadian patent, expanding its OptiMAL® antibody library IP portfolio.

What the company is saying

Fusion Antibodies plc reports the grant of Canadian patent CA 3115150, titled 'Antibody Library and Method', by the Canadian Intellectual Property Office. The announcement highlights that this patent covers two antibody families and related design methods, positioning it as complementary to the company's OptiMAL® library offering. The company frames this as a step in building its intellectual property base for applications such as antibody discovery, affinity maturation, and sequence optimisation. Fusion emphasises its operational track record, citing over 750 antibodies sequenced or expressed and more than 250 humanisation projects since 2012, along with a client roster including eight of the top 10 global pharmaceutical companies by revenue. The tone is factual and measured, focusing on the operational and IP milestone rather than projecting immediate commercial impact. The release also notes ongoing efforts to secure similar patents in other jurisdictions, including Europe and China. No financial figures, revenue impacts, or commercialisation timelines are discussed.

What the data suggests

The announcement confirms the successful grant of a Canadian patent for two antibody families and their design methods, with the patent number and grant date specified. Operationally, Fusion has sequenced or expressed over 750 antibodies and completed more than 250 humanisation projects since 2012, indicating sustained activity in antibody engineering. The client base includes eight of the top 10 global pharmaceutical companies by revenue, suggesting credibility and industry relevance. No financial data, revenue figures, or direct commercial outcomes tied to this patent are disclosed. The only forward-looking elements are expectations that the patent will complement existing offerings and that further patent applications are underway in other regions, but no timelines or quantifiable targets are provided. The announcement is strictly an IP milestone update, not a commercial or financial inflection point.

Analysis

The announcement is primarily factual, confirming the grant of a Canadian patent (CA 3115150) and providing specific operational history (over 750 antibodies sequenced/expressed, over 250 humanisation projects, eight of the top 10 pharma clients). The only forward-looking claims are that the patent is 'expected to be complementary' to the company's offering and that additional patent applications are being progressed in other territories, but these are not exaggerated or presented as imminent revenue drivers. There is no mention of large capital outlays, commercialisation timelines, or financial projections, and no attempt to inflate the significance of the patent grant beyond its factual scope. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be stronger than weak_positive, but the operational and IP milestones are credible and proportionately presented. No hype language or overstatement is present.

Risk flags

• ●The absence of any disclosed commercial agreements or revenue linked to the new patent means the financial impact remains speculative. Without evidence of licensing, product launches, or customer uptake tied to this IP, the announcement is not yet a revenue catalyst.
• ●Patent protection in Canada does not guarantee similar outcomes in other key markets such as Europe or China. Delays or denials in those jurisdictions could limit the global value of the OptiMAL® library platform.
• ●No information is provided on the competitive landscape or whether similar patents exist, making it difficult to assess the defensibility or uniqueness of Fusion's IP position.

Bottom line

Fusion Antibodies' Canadian patent grant strengthens its intellectual property position for the OptiMAL® antibody library, but the announcement does not provide evidence of immediate commercial impact or financial upside. The company demonstrates operational credibility with a history of over 750 antibodies sequenced or expressed and a client base that includes major pharmaceutical companies. However, without disclosed licensing deals, revenue projections, or commercial milestones tied to this patent, the development is best viewed as a necessary but not sufficient step toward monetisation. Investors should watch for future updates on patent approvals in other regions and any concrete commercial agreements leveraging this IP. The key takeaway is that this is an incremental IP milestone, not a near-term earnings catalyst.

Announcement summary

(AIM: FAB) Fusion Antibodies plc announces that its patent application no. CA 3115150, entitled "Antibody Library and Method", has been granted by the Canadian Intellectual Property Office. The Patent covers two families of antibodies and the method for the design of such antibody libraries. The grant follows the receipt of a notice of allowance from the Canadian Patent Office, previously announced on 22 June 2026. The Patent is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation. Fusion continues to progress additional patent applications in respect of the OptiMAL® Library in several other territories worldwide including Europe and China. Fusion Antibodies plc specialises in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and completed over 250 humanisation projects. The Company has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

Disagree with this article?